Fusion Antibodies - Leaders in development of antibodies for both therapeutic drug & diagnostic applications. Specialists in discovery to clinical supply
Location: United Kingdom, Northern Ireland, Belfast
Employees: 11-50
Total raised: $2.5M
Founded date: 2000
Investors 2
| Date | Name | Website |
| - | Co-FundNI | cofundni.c... |
| - | Clarendon ... | clarendon-... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.07.2007 | - | $2.5M | - |
Mentions in press and media 6
| Date | Title | Description |
| 06.12.2021 | Fusion Antibodies : Interim Report 2021 | Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information for the purposes of Article 7 under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With t... |
| 01.04.2021 | FUSION ANTIBODIES PLC Fusion Antibodies : proud to support ‘State of the Art' project | Northern Ireland Science Festival, in conjunction with Linen Biennale and funded by Northern Ireland Arts and Business, recently rolled out the virtual red carpet to premier Fusion Antibodies Head of Scientific Affairs, Dr Anthony O'Kane's ... |
| 20.11.2020 | FUSION ANTIBODIES PLC Fusion Antibodies : Interim Report 2020 | Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information for the purposes of Article 7 under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With t... |
| 20.11.2020 | Fusion Antibodies : Interim Report 2020 | Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information for the purposes of Article 7 under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With t... |
| 31.05.2012 | Selexis SA and Fusion Antibodies Services Form Partnership | |
| 26.07.2007 | Fusion Antibodies raises $2.5M for antibody tech | Fusion Antibodies, an Irish biotech focused on — you guessed it — antibody tools and drugs, raised $2.5 million (£1.2 million) to push unidentified drug candidates through animal testing. Participants in the round included Crescent Capital,... |